ClinicalTrials.gg
CompletedNCT04928144Updated Mar 23, 2022

Phase 1 Study of SHJ002 Sterile Ophthalmic Solution in Pediatric Subjects

A Phase 1 interventional study of SHJ - Low concentration and SHJ - Mid concentration in Myopia, sponsored by Sunhawk Vision Biotech, Inc.. Completed at 1 site in Taiwan. Open to participants aged 10 Years to 15 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Sunhawk Vision Biotech, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
10 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Myopia with a site in Taiwan — 6 open to participants now, 8 under way, none of them phase 3. Myopia · Taiwan.

Enrollment
31st of 31
12 · median 65
Started
2021
with 3 others
Phase 1
4 of 40
none open now
Registered
19th of 40
by date
Lead sponsor
2 of 40
Sunhawk Vision Biotech, Inc.

Among the 40 studies in Myopia with a site in Taiwan, this one is the 31st largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2021, is one of 4 in phase 1, and was the 19th registered.

Myopia

1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

6 of the 40 studies in Myopia with a site in Taiwan are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 10 Years to 15 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Myopia with a site in Taiwan, or all of them as a file.
02

Study summary

This is a single-center, open-label, first-in-human dose-escalation study of SHJ002 Ophthalmic Solution in children. (Part 1) Three (3) subjects will receive each concentration of SHJ002 for 3 days in an escalation design in one eye. (Part 2) A Group of 9 additional children will receive the highest tolerated concentration for 28 days.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Myopia
04

Who can participate

Ages eligible
10 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-cycloplegic sphere from +1.50 to -4.75 Diopters in one or both eyes.
  • A minor able to complete all study assessments and comply with the protocol and has a parent or caregiver willing and able to follow study instructions, comply with the protocol and attend study visits with the subject as required, in the opinion of the Investigator.
  • Literate and able to orally communicate.

Exclusion criteria

Exclusion Criteria:

  • Non-cycloplegic sphere worse than -4.75 Diopters
  • Axial length > 26 mm
  • Hyperopia worse than +1.50 Diopters
  • Anisometropia (difference of myopic power >2.00 D).
  • Astigmatism > 1.5 D.
  • Intraocular pressure > 21 mm Hg or \< 6 mm Hg.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    0.025% SHJ002

    0.025% SHJ002 Sterile Ophthalmic Solution

    Drug: SHJ - Low concentration

  • Experimental
    0.080% SHJ002

    0.080% SHJ002 Sterile Ophthalmic Solution

    Drug: SHJ - Mid concentration

  • Experimental
    0.25% SHJ002

    0.25% SHJ002 Sterile Ophthalmic Solution

    Drug: SHJ - High concentration

  • Experimental
    SHJ002 - Maximum tolerated concentration

    Maximum tolerated concentration of SHJ002

    Drug: SHJ - Maximum tolerated

Interventions

  • DrugSHJ - Low concentration

    Topical ophthalmic

  • DrugSHJ - Mid concentration

    Topical ophthalmic

  • DrugSHJ - High concentration

    Topical ophthalmic

  • DrugSHJ - Maximum tolerated

    SHJ - Maximum tolerated

06

What researchers measure

Primary outcomes

  1. Change from baseline in best corrected visual acuity

    Change from baseline in best corrected visual acuity

    Time frame: 3 days (Part 1) and 28 days (Part 2)

  2. Incidence of Adverse Events

    Incidence of Adverse Events

    Time frame: 3 days (Part 1) and 28 days (Part 2)

07

Study locations

1 site
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jun 16, 2021
StartActual
Jul 2, 2021
Primary completionActual
Sep 17, 2021
CompletionActual
Sep 17, 2021
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04928144
Lead sponsor
Sunhawk Vision Biotech, Inc.
Responsible party
Sponsor
First posted
Jun 16, 2021
Start date
Jul 2, 2021
Primary completion
Sep 17, 2021
Completion
Sep 17, 2021
Last update
Mar 23, 2022

Study contacts

Suh-Hang H. Juo, MD, Ph.D.
study director · Sunhawk Vision Biotech, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion